TEVA Plunges on Q1 Results
Market News

TEVA Plunges on Q1 Results

Shares of Teva Pharmaceutical (NYSE:TEVA) are down today after it reported earnings for its first quarter of Fiscal Year 2023. Adjusted earnings per share came in at $0.40, which missed analysts’ consensus estimate of $0.56 per share. Sales were flat year-over-year, with revenue hitting $3.7 billion. This was $110 million above expectations.

Looking forward, management now expects revenue and adjusted EPS for Fiscal Year 2023 to be in the ranges of $14.8 billion to $15.4 billion and $2.25 to $2.55, respectively. For reference, analysts were expecting $14.92 billion in revenue and an EPS figure of $2.40.

A look at the past five trading days for TEVA stock highlights the level of impact today’s news had on it. Indeed, shares fell over 7% at the time of writing. As a result, investors are now down 3.66% during this timeframe.

Disclosure

Related Articles
TheFlyTeva put volume heavy and directionally bearish
TheFlyTeva price target raised to $22 from $21 at Barclays
TheFlyTeva reiterates FY27 revenue growth view up mid-single digits
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App